RAS family variants—most of which involve KRAS—are the most commonly occurring
hotspot mutations in human cancers and are associated with a poor prognosis. For almost …

KRAS mutations drive oncogenic alterations in numerous cancers, particularly in human
pancreatic ductal adenocarcinoma (PDAC). About 93% of PDACs have KRAS mutations …

Activating KRAS mutations (KRAS*) in pancreatic ductal adenocarcinoma (PDAC) drive
anabolic metabolism and support tumor maintenance. KRAS* inhibitors show initial …

As an iron dependent regulatory cell death process driven by excessive lipid peroxides
(LPO), ferroptosis is recognized as a powerful weapon for pancreatic cancer (PC) therapy …

Despite significant advancements in the treatment of other cancers, pancreatic ductal
adenocarcinoma (PDAC) remains one of the world's deadliest cancers. More than 90% of …

SPTBN2 is a protein-coding gene that is closely related to the development of malignant
tumors. However, its prognostic value and biological function in pan-cancer, especially …

Overexpression of human epidermal growth factor receptor 2 (HER2) in breast cancer is an
important target of monoclonal antibody (mAb) therapy such as trastuzumab. Due to the …

Pancreatic cancer has a dismal prognosis due to late detection and lack of efficient
therapies. The Kirsten rat sarcoma virus (KRAS) oncogene is mutated in up to 90% of all …

Pancreatic cancer is a highly lethal disease with a 5-year survival rate of around 11–12%.
Surgery, being the treatment of choice, is only possible in 20% of symptomatic patients. The …

Introduction KRAS is a critical oncogenic protein intricately involved in tumor progression,
and the difficulty in targeting KRAS has led it to be classified as an 'undruggable …